Koch Institute

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 6, 2024
Investment, NSCLC, Therapy, The, Cancer, Metabolism, Merck, Research, Research and development, Equilibrative nucleoside transporter 1, SITC, AACR, Koch Institute, Hub, ENT1, Immunity, Comprehension, Adenosine, Lymphocyte, Merck & Co., Administration, Patient, TIGIT, Survival, Place of birth, HNSCC, Immune system, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
  • “With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects.
  • We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024.
  • On December 7, 2023, iTeos announced the appointment of David K. Lee to the Company’s Board of Directors.

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Retrieved on: 
Tuesday, February 27, 2024
Progression-free survival, PFS, Woman, Research, Break, Reproductive medicine, Immunotherapy, University, Ovarian cancer, Cancer, DNA repair, Koch Institute, Bevacizumab, Gynecologic Oncology (journal), MD Anderson Cancer Center, Patient, MRD, SLL, Survival, Medical imaging

LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in the Phase 2 OVATION 2 Study for the localized treatment of advanced ovarian cancer.

Key Points: 
  • LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in the Phase 2 OVATION 2 Study for the localized treatment of advanced ovarian cancer.
  • We believe this combination therapy holds promise based on our preclinical animal studies, which showed strong synergies between IMNN-001 and bevacizumab.
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs. chemotherapy plus bevacizumab and IMNN-001.

GradSchoolCenter.com Releases Its Top Picks for the Graduate Research Centers That Are Making a Real Difference

Retrieved on: 
Wednesday, January 3, 2024
Disease, Yale University, UCLA, University, School, Student, Research, Brain, Vanderbilt University, MIT, Koch Institute, Cornell University, Johns Hopkins University, Harvard–Smithsonian Center for Astrophysics, AIMS, Alzheimer's disease, Ageing, Artificial intelligence, Stanford University, Columbia University, Arizona State University, Cancer, Duke University, Yale Cancer Center, Interdisciplinarity, Ohio State University, Texas A&M University, Coffee, Cornell Lab of Ornithology, Disorder, Harvard University, Nursing

NASHVILLE, Tenn., Jan. 3, 2024 /PRNewswire/ -- GradSchoolCenter.com has named the 20 graduate research centers that are integral to facilitating research and innovation efforts for academic and scientific advancement and to benefit the community at large.

Key Points: 
  • NASHVILLE, Tenn., Jan. 3, 2024 /PRNewswire/ -- GradSchoolCenter.com has named the 20 graduate research centers that are integral to facilitating research and innovation efforts for academic and scientific advancement and to benefit the community at large.
  • Numerous universities across America are a treasure trove for state-of-the-art research centers that significantly contribute to society.
  • Below is a link to our ranking report:
    We chose these schools based on the current and potential positive impact they make on society.
  • According to our lead researcher, Wendy Pigford, "The research centers are a hub for groundbreaking discoveries where engineers, scientists, and other accomplished experts in their fields collaborate with fellows and graduate students to cultivate an atmosphere of excellence."

The Galien Foundation Honors 2023 Prix Galien Award Recipients

Retrieved on: 
Friday, October 27, 2023
American Cancer Society, Physiology, Medical genetics, Fred Hutchinson Cancer Research Center, Health technology, P. Roy Vagelos, Peace Corps, Incubator, University of Washington, NASA, Merck, Prix, Creativity, Tufts University School of Medicine, Koch Institute, Endeavour, MIT Jameel Clinic, Digital health, National Aeronautic Association, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Human Genome Sciences, African, ARD International Music Competition, Patient, Doctor of Philosophy, Nursing, Pharmaceutical industry, Biophysics, Biology

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year's award winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Product for Rare/Orphan Diseases," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity" and "Best Startup."

Key Points: 
  • "We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry," said Bruno Cohen, Chairman of The Galien Foundation.
  • "Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare."
  • The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement.
  • With chapters in 14 countries and Africa, and an inaugural chapter being established in India in 2024, Prix Galien is regarded worldwide as the equivalent of the Nobel Prize for the life science industry.

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

Retrieved on: 
Wednesday, October 18, 2023
Ovarian cancer, Bevacizumab, Patient, Research, Progression-free survival, SLL, Break, Koch Institute for Integrative Cancer Research, PFS, Gynecologic Oncology (journal), Koch Institute, DNA repair, Reproductive medicine, Clinical trial, MRD, Immunotherapy, University, Woman, Cancer, MD Anderson Cancer Center, Massachusetts Institute of Technology School of Engineering, Medical imaging

LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).
  • This Phase 1/2 trial is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer.
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs. chemotherapy plus bevacizumab and IMNN-001.

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"

Retrieved on: 
Thursday, July 27, 2023
Heart, Tufts University School of Medicine, University, Doctor of Philosophy, Fred Hutchinson Cancer Research Center, MIT Jameel Clinic, University of Washington, Human Genome Sciences, Koch Institute, Merck, American Cancer Society, Koch Institute for Integrative Cancer Research, Medical genetics, Physiology, Pharmaceutical industry, Biophysics, Biology

NEW YORK, July 27, 2023 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2023 Prix Galien USA Award nominees for "Best Biotechnology Product", and "Best Pharmaceutical Product." Nominees have also been announced in the newest Prix Galien Award category, "Best Product for Rare/Orphan Diseases." Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2023, at the American Museum of Natural History in New York City. 

Key Points: 
  • "The annual Prix Galien USA Awards provide the opportunity to recognize the incredible achievements of those at the forefront of healthcare innovation, which have become the backbone of many biomedical and technology advances," said Bruno Cohen, Chairman of The Galien Foundation.
  • "We look forward to honoring the most impactful innovations of our generation, center stage, in the heart of New York City."
  • The Prix Galien USA Awards Committee is composed of 11 renowned leaders from the biomedical industry and academia, including three Nobel Laureates, responsible for evaluating nominees.
  • M.D., Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc.
    Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington
    Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington
    Ph.D., Nobel Laureate, Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic

Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

Retrieved on: 
Thursday, June 1, 2023
Convention center, Boston Convention and Exhibition Center, Koch Institute, SAN, Conference, Koch Institute for Integrative Cancer Research, EDT, MIT

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:

Key Points: 
  • SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:
    BIO International Convention, being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, MA.
  • Ms. Johnson will provide a corporate overview on Tuesday, June 6th at 12:00 p.m. EDT.
  • Longwood Healthcare Leaders Spring 2023 MIT Conference, being held June 7-8, 2023 at the Koch Institute at MIT, Cambridge, MA.
  • Ms. Johnson will participate in a panel discussion on Thursday, June 8th at 3:40 p.m. EDT:

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Retrieved on: 
Tuesday, April 25, 2023
The Ride to Conquer Cancer, Sidney Kimmel, Sreyashi Jhumki Basu, GBM, Research group, Ovarian cancer, Pancreatic cancer, Cancer, Research, Koch Institute, MIT, CD73, Genomics, The Institute, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Associate, Science, Physician, Sidney Kimmel Comprehensive Cancer Center, University, Escape Room, Drug development, Knowledge, Koch Institute for Integrative Cancer Research, TeamLab (art collective), Johns Hopkins, Break, Tumor microenvironment, Nanobiotechnology, Vaccine, Medical imaging

CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.

Key Points: 
  • They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.
  • The Break Through Cancer Scientists were carefully selected based on their expertise in early diagnostics, single cell genomics data and materials science, and specific types of cancer.
  • "These newly named Break Through Cancer Scientists have cultivated stellar reputations and demonstrated outstanding success in working across scientific disciplines to establish a collaborative environment.
  • A Research Group Leader at The University of Texas MD Anderson Cancer Center's Pancreatic Cancer Research Center, Paola leads innovative research on patient-derived models and biospecimens.

EMIT IMAGING Collaborates with MIT Koch Institute for Integrative Cancer Research to Enhance Cryo-Fluorescence Tomography Technology

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Technology, Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Research, Software, Science, Hardware, Koch Institute for Integrative Cancer Research, Workflow, 3D, Cancer, Koch Institute, MIT, CFT, Behavior, Organization, Protein, Business, EMIT, Disease, Medical imaging

EMIT IMAGING, Inc. (“EMIT”), the leader in Cryo-Fluorescence Tomography (CFT), is proud to announce a project with the MIT Koch Institute for Integrative Cancer Research to enhance EMIT’s novel 3D imaging technology.

Key Points: 
  • EMIT IMAGING, Inc. (“EMIT”), the leader in Cryo-Fluorescence Tomography (CFT), is proud to announce a project with the MIT Koch Institute for Integrative Cancer Research to enhance EMIT’s novel 3D imaging technology.
  • By working with the Koch Institute, EMIT aims to bring its technology to the forefront of cancer research, improving biological and drug research.
  • "We are thrilled to be working with the Koch Institute for Integrative Cancer Research, a world-renowned leader in cancer research," said Dr. Matthew Silva, CEO at EMIT.
  • EMIT IMAGING is the leader of Cryo-Fluorescence Tomography (CFT) imaging and is pioneering hardware, software, and data science methods.

The Galien Foundation Appoints Michael Rosenblatt, M.D., as Chairman of Prix Galien USA Awards Committee

Retrieved on: 
Thursday, January 5, 2023
Knowledge, Linda, University of Washington, Columbia University Irving Medical Center, Human Genome Sciences, Bill & Melinda Gates Foundation, Merck & Co., Medtech, Medical genetics, Research, Koch Institute, Merck, Bill, Physiology, Mayo Clinic College of Medicine and Science, Fred Hutchinson Cancer Research Center, Patient, MIT Jameel Clinic, Committee, Pleasure, Affiliation, Mayo, Mayo Clinic, Health, American Cancer Society, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Flagship Pioneering, Pharmaceutical industry, Management, Nobel, Biophysics, Medicine, Biology

"Following the illustrious leadership of both P. Roy Vagelos and then Susan Desmond-Hellmann in this role, I am deeply honored to serve as the next Chairman of the Prix Galien USA Committee.

Key Points: 
  • "Following the illustrious leadership of both P. Roy Vagelos and then Susan Desmond-Hellmann in this role, I am deeply honored to serve as the next Chairman of the Prix Galien USA Committee.
  • The Prix Galien recognizes the teams in the biopharmaceutical industry that have created the most important innovations that improve health and address unmet medical needs.
  • I am most enthusiastic about taking on new responsibilities to advance the mission of The Galien Foundation.
  • I look forward to October 26, 2023, when we announce the next group of Prix Galien USA awardees and celebrate their achievements."